Other languages Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Real-time Estimate Cboe BZX Other stock markets 10:24:44 2024-07-09 am EDT			5-day change	1st Jan Change
0.152 ^USD	-6.23%		-25.10%	-89.96%

Jul. 05	Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split	MT
Jul. 02	Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split	Jul. 05
Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors	Jun. 27
Sector Update: Health Care Stocks Advance Late Afternoon	Jun. 10
Sector Update: Health Care	Jun. 10
Calidi Biotherapeutics Signs Virotherapy Deal With Siga Technologies -- Calidi Shares Surge Pre-Bell	Jun. 10
Calidi Biotherapeutics Collaborates with Siga Technologies to Advance Calidi?S Revolutionary Rtnova Virotherapy for Lung Cancer and Metastatic Solid Tumors	Jun. 10
Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting	Jun. 03
Calidi Biotherapeutics, Inc. Announces Resignation of David Lapre as Director	May. 16
Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07
Calidi Biotherapeutics to Sell Common Stock	Feb. 07
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments	Jan. 08
Calidi Biotherapeutics Announces Directorate Changes	Dec. 12
Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board	Dec. 05
Calidi Biotherapeutics Gets US Patent for Cancer Treatment Technology Platform	Nov. 20
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting	Nov. 03
Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment	Nov. 01
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer	23-10-27
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director	23-10-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Other languages

Filters